Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue
−0.28%
EPS
−157.5%
Free cash flow
+38.8%
Total debt
−18.1%

Quarter to September 2026, against a year earlier

19.83 0.86 +4.53%
Market cap
$21.8B
P/E
0.0×
Fwd P/E
82.6×
Dividend yield
2.42%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100

Viatris Inc. 10-K filed Feb 27, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed · accepted 4:07 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business: no comparison — no earlier filing on file